The committee based its decision on data showing the subcutaneous formulation of Opdivo was not inferior to the intravenous formulation.

Opdivo plus Yervoy demonstrated superior median EFS and overall survival rates compared to chemotherapy in resectable NSCLC. The combination therapy showed higher pathologic complete response and ...

The European Commission (EC) has granted approval for Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) in combination with the ...

Opdivo plus Yervoy showed a median overall survival of 23.7 months vs. 20.6 months with lenvatinib or sorafenib in the CheckMate -9DW trial. The overall response rate for Opdivo plus Yervoy was 36 ...

Bristol Myers Squibb (NYSE:BMY) announced Saturday that its checkpoint inhibitors Opdivo and Yervoy, when combined, reduced the risk of disease progression or death by 38% in a Phase 3 trial for ...

Opdivo/Yervoy has been approved since 2018 as first-line treatment for patients with intermediate- and poor-risk advanced RCC, and BMS was hoping to extend the use of the regimen into patients ...

For BMS, it is a second big win in two days, as just yesterday its Opdivo and Yervoy combo in kidney cancer showed big advantages for patients. This time it was Opdivo versus Yervoy in CHECKMATE ...

The FDA accepted a supplemental biologics license application for Opdivo plus Yervoy as a first-line treatment for some adult and pediatric patients with colorectal cancer. The Food and Drug ...